1. Home
  2. ACRV vs MPAA Comparison

ACRV vs MPAA Comparison

Compare ACRV & MPAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRV
  • MPAA
  • Stock Information
  • Founded
  • ACRV 2018
  • MPAA 1968
  • Country
  • ACRV United States
  • MPAA United States
  • Employees
  • ACRV 61
  • MPAA N/A
  • Industry
  • ACRV Medicinal Chemicals and Botanical Products
  • MPAA Auto Parts:O.E.M.
  • Sector
  • ACRV Health Care
  • MPAA Consumer Discretionary
  • Exchange
  • ACRV Nasdaq
  • MPAA Nasdaq
  • Market Cap
  • ACRV 73.5M
  • MPAA 154.5M
  • IPO Year
  • ACRV 2022
  • MPAA 1994
  • Fundamental
  • Price
  • ACRV $2.24
  • MPAA $9.35
  • Analyst Decision
  • ACRV Strong Buy
  • MPAA
  • Analyst Count
  • ACRV 6
  • MPAA 0
  • Target Price
  • ACRV $21.80
  • MPAA N/A
  • AVG Volume (30 Days)
  • ACRV 162.1K
  • MPAA 134.5K
  • Earning Date
  • ACRV 05-13-2025
  • MPAA 02-10-2025
  • Dividend Yield
  • ACRV N/A
  • MPAA N/A
  • EPS Growth
  • ACRV N/A
  • MPAA N/A
  • EPS
  • ACRV N/A
  • MPAA N/A
  • Revenue
  • ACRV N/A
  • MPAA $753,727,000.00
  • Revenue This Year
  • ACRV N/A
  • MPAA $7.30
  • Revenue Next Year
  • ACRV N/A
  • MPAA $5.96
  • P/E Ratio
  • ACRV N/A
  • MPAA N/A
  • Revenue Growth
  • ACRV N/A
  • MPAA 4.26
  • 52 Week Low
  • ACRV $2.14
  • MPAA $4.36
  • 52 Week High
  • ACRV $11.90
  • MPAA $11.89
  • Technical
  • Relative Strength Index (RSI)
  • ACRV 22.41
  • MPAA 42.95
  • Support Level
  • ACRV $5.00
  • MPAA $9.95
  • Resistance Level
  • ACRV $5.65
  • MPAA $10.36
  • Average True Range (ATR)
  • ACRV 0.44
  • MPAA 0.67
  • MACD
  • ACRV -0.33
  • MPAA -0.23
  • Stochastic Oscillator
  • ACRV 2.85
  • MPAA 10.73

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

About MPAA Motorcar Parts of America Inc.

Motorcar Parts of America Inc is a supplier of automotive aftermarket non-discretionary replacement parts and test solutions and diagnostic equipment. It operate in the non-discretionary automotive aftermarket for replacement hard parts in North America and includes products such as light-duty rotating electrical products, wheel hub products, brake-related products, and turbochargers. In addition, it sell test solutions and diagnostic equipment. The company operates in three segments Hard Parts, Test Solutions and Diagnostic Equipment and Heavy Duty. Key revenue is generated from Hard Parts, which includes (i) light duty rotating electric products such as alternators and starters, (ii) wheel hub products, (iii) brake-related products, including brake calipers, brake boosters, brake rotors.

Share on Social Networks: